Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

SEATTLE, June 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).  

  • The U.S. Food and Drug Administration (FDA) approved the Los Angeles immunotherapy manufacturing facility on June 29, 2011. The facility includes 36 workstations, and Dendreon will bring these on in a staged approach.
  • In addition, the Centers for Medicare and Medicaid Services (CMS) issued a final National Coverage Decision (NCD) for PROVENGE on June 30, 2011, requiring Medicare contractors to cover the use of PROVENGE for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The NCD will standardize coverage processes across the country for all Medicare patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and provides the local Medicare Administrative Contractors (MACs) specific criteria, consistent with the label, on how PROVENGE should be covered.
  • PROVENGE was issued a product specific Q-code effective July 1, 2011, which allows for electronic submission of claims and is expected to accelerate time to payment for physicians.  
  • As part of this expanded access, Dendreon supports programs to provide comprehensive assistance for eligible patients seeking access to treatment with PROVENGE, including through grants to independent foundations and establishment of a patient assistance program for uninsured patients. Dendreon provides grants to independently run foundations providing qualifying patients with fin
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from ... three key industry events beginning with Patient-Centered Clinical Trials ... in Boston , September 4-5. Patient recruitment ... and Aaron Fleishman will share insights on the ... a variety of tactics – from media to mobile apps ...
(Date:8/28/2014)... MENLO PARK, Calif. , Aug. 28, 2014 ... company focused on developing novel mid- to late-stage ... raised $7.0 million in its first round of ... AshHill Biomedical Investments and Hercules Bioventures with participation ... biotech entrepreneur and pharmaceutical executive, Dr. Larry ...
(Date:8/28/2014)... Woodstock, Vt. (PRWEB) August 28, 2014 ... microbiology testing around the world is available from ... industrial diagnostics companies. “ Industrial Microbiology Market Review, ... the Industrial Market ” (IMMR—4) tracks and compares ... in in North America, Europe and Asia, and ...
(Date:8/28/2014)... 2014 Supplementing their complete line ... for Eppendorf Safe Lock Centrifuge Tubes . ... highest quality tubes at an affordable price. Eppendorf ... doing chemical, medical, pharmaceutical, and life science research ... regularly able to afford Eppendorf products. , Eppendorf ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... A tiny scaffold-like titanium structure of Nanonets coated ... lighter and longer-lasting Lithium-ion batteries, according to a team ... material using nanotechnology. The web-like Nanonets developed in ... offer a unique structural strength, more surface area and ...
... , , , SAN DIEGO , ... BMR ) today announced the signing of an amendment to ... its 301 Binney Street laboratory research facility in Cambridge, Massachusetts ... of laboratory and office space contiguous to its existing premises located ...
... SAN FRANCISCO , Feb. 16 ... innovative new initiatives at Informex this week, highlighting the country,s ... the global chemicals industry. , At Informex 2010, Scotland ... seven leading universities, the private sector and the Scottish Government ...
Cached Biology Technology:Silicon-coated nanonets could build a better lithium-ion battery 2BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 2BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 3BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 4Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 2Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 3Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 4
(Date:8/28/2014)... Aug. 28, 2014  Privacy Advocate and Senior Staff ... Lynch , joins the lineup of biometric and mobile ... Biometrics UnPlugged Executive Summit in Tampa, Florida ... Previously announced speakers include Steven Rahman, Director, Technology and Strategy ... at Experian. The theme of this year,s event is ...
(Date:8/28/2014)... and imaging how quickly blood flows in the brain ... abuse affects the brain, which may aid in improving ... treatment options for recovering drug addicts. The new method, ... University in New York, USA and the U.S. National ... Society,s (OSA) open-access journal Biomedical Optics Express ...
(Date:8/28/2014)... pose a significant health risk to people with asthma according ... Allergy and Clinical Immunology . , By critically reviewing the ... has found that the presence of several types of mould ... as increasing the likelihood of developing the condition. , The ... of Exeter Medical School and is the first time all ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2
... new fungal species, called , Hebelomagriseopruinatum , has now ... fungus, whose name can be translated into ,the grey-dewy ... a mushroom-hunting tour headed by postdoc Jacob Heilman-Clausen from ... in 2009, postdoc Jacob Heilman-Clausen from the Center for ...
... with Primary Angle Closure Glaucoma (PACG), a leading cause ... people worldwide, 80% of whom live in Asia. ... Nature Genetics , on 26 August 2012, was ... Institute (SERI)/Singapore National Eye Centre (SNEC), Genome Institute of ...
... /PRNewswire-iReach/ -- IdentiSys Inc., North America,s largest sales ... emergency response and access control/CCTV security systems, ... Security and Presentation Divisions of Mountainland Business ... with additional offices in Idaho, Oregon, Nevada, ...
Cached Biology News:New Danish fungal species discovered 2Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 2Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 3IdentiSys acquires the Identification, Security and Presentation Divisions of Mountainland Business Systems, a Utah based reseller 2IdentiSys acquires the Identification, Security and Presentation Divisions of Mountainland Business Systems, a Utah based reseller 3
... Immunogen: Immunogen corresponds to ... detects human SKAP55.,PA1-525 has been successfully used ... By Western blot, this antibody detects ... Jurkat cells.This antibody has also been used ...
... chromatography, Affi-Prep protein A media yield ... IgG prior to analysis of other ... for antigen purification. Protein A binds ... especially IgG from mammalian species. This ...
Determin interaction of your protein with Echelons lipids...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
Biology Products: